Childhood Atropine For Myopia Progression
AssigneeVyluma Inc.
InventorsTung Fong, Kumaresh Soppimath, Simon P. Chandler, Raul Arturo Trillo, Tushar Hingorani
Life of this patent
Estimating the term…
Abstract
Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.
Claims41
A method of optimizing treatment for reducing myopia progression using topical atropine administration in a subject having an initial spherical equivalent refraction (SER) of at least −0.50 D as measured by cycloplegic autorefraction, comprising:
- topically administering a quantity of a sterile and storage stable low-dose atropine formulation to an eye of the subject for a period of at least one year;
- wherein the atropine formulation has a low strength buffer, has a pH between 5.0 and 6.0, and contains about 0.01% atropine or atropine sulfate;
- wherein the atropine formulation is administered daily;
- and
- wherein daily administration of the atropine formulation results in equal or less than 0.50 D myopia progression after at least one year.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing myopia progression in a subject having an initial spherical equivalent refraction (SER) of at least −0.50 D as measured by cycloplegic autorefraction, comprising:
- topically administering a quantity of a storage stable low-dose atropine formulation to an eye of the subject for a period of at least one year;
- wherein the atropine formulation is administered daily;
- wherein the atropine formulation contains about 0.01% atropine or atropine sulfate;
- and
- wherein upon daily administration of the atropine formulation results in equal or less than 0.50 D myopia progression after at least one year.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
41-60. (canceled)
Dependencies are inferred from the claim text.